Efficacy of oral and intravenous XXXX in @entity943 .

@entity1 @entity943 @entity16949
To evaluate the efficacy of oral and intravenous @entity16949 , a new class IC antiarrhythmic agent, 3 separate protocols were performed in @entity1 with benign or potentially lethal @entity943 . An open-label intravenous trail in 10 @entity1 was conducted using a dose of 1.7 mg/kg/min under constant monitoring. An oral short-term in-hospital trial in 20 @entity1 (8 @entity1 entered directly from the intravenous short-term trial) was conducted using a single-blind placebo dose titration protocol in which 50 mg of @entity16949 every 8 hours was increased at 3-day intervals to 75 mg, and then 100 mg every 8 hours depending on the observed change in @entity943 frequency by Holter monitoring. Finally, an outpatient long-term oral trial was conducted in 17 of the 20 @entity1 who completed the inpatient oral short-term trail. Two of the 10 @entity1 from the inpatient intravenous trail did not enter the oral trial, because a proarrhythmic response developed in 1 and because of a lack of efficacy in the other. During the inpatient oral trial, 17 of 20 @entity1 (85%) responded to @entity16949 and entered the long-term phase. Two of these @entity1 were removed from the trial because of lack of efficacy at 3 and 10 months, respectively. In the oral therapy protocols, minor side effects of the central nervous system occurred in 4 of 17 @entity1 (24%). Six of 20 @entity1 (30%) each had more than a 25% increase in PR and QRS duration that was not associated with higher degrees of block.(ABSTRACT TRUNCATED AT 250 WORDS)
